Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial
{{output}}
Background: WHO recommends a boost COVID-19 vaccine dose for people with immunosuppression, including people living with HIV. Data from randomised controlled trials assessing approaches to homologous and heterologous COVID-19 vac... ...
